Osteoarthritis Management: The Next Generation

canine osteoarthritis management
Antinol® RAPID is the latest advancement in our multimodal approach to canine osteoarthritis management.

This article is sponsored content brought to you by Cenvet.

Antinol® RAPID is the latest advancement in our multimodal approach to canine osteoarthritis management, offering veterinarians an effective and safe long-term option.

Since its launch in Australia back in 2018, Antinol® has become a keystone in osteoarthritis management protocols for hundreds of veterinary practices, with over 800 clinics in Australia now stocking it. 

With the ever-increasing popularity of Antinol®, we have recently announced the next generation: Antinol® RAPID! Over the past few months, most veterinarians have switched to the new Antinol® RAPID formulation, which had been years in development and has surpassed all expectations.

Antinol® RAPID is the latest advancement in our multimodal approach to canine osteoarthritis management, offering veterinarians an effective and safe long-term option. The active ingredient consists of two components. The first is PCSO-524® (the main active in Antinol®), a marine lipid compound extracted from Green Lipped Mussel Powder via a patented process called Supercritical Fluid Extraction. PCSO-524® is then mixed with a proprietary high-phospholipid krill extract via the same process, creating a patented active compound known as EAB-277™.

While PCSO-524® and krill extracts are effective anti-inflammatory compounds in their own right, laboratory studies have proven that the synergistic blend of EAB-277™ in Antinol® RAPID represents a more potent anti-inflammatory combination, more effective than either product alone. 

As a nutraceutical, Antinol® is amongst the most researched and published non-drug compound in veterinary medicine today, with two separate force-plate analysis studies demonstrating similar efficacy against NSAIDs with no associated side effects1,2. Research is ongoing, with investigations into other indications for skin, cognitive and respiratory support being a priority. 

Decades of published peer-reviewed research firmly establishes Antinol® and Antinol® RAPID as superior to other natural joint products. 

Antinol® RAPID has an excellent safety track record, with no documented side effects and no known contraindications. It can therefore be used in a versatile fashion, to be combined with NSAIDs, injectables or other pharmaceuticals and supplements for enhanced case management options and long-term patient support. 

Veterinarians have also shared some successful off-label uses for Antinol® RAPID. Due to the unique combination of lipids and absence of any allergenic proteins in EAB-277™, the product is being applied by veterinarians to manage skin and coat health as well as other inflammatory conditions. The use of Antinol® in cats has also been reported by veterinarians, especially as an alternative or adjunctive therapy for NSAIDs in many patients. Antinol® use in cats is considered off-label in Australia, but is used widely in overseas markets.  

Antinol® RAPID also comes with a 45 day 100% money-back guarantee for satisfaction and palatability.

Over the past years, pet owners have been so impressed with Antinol® that stories of their pets and how Antinol® had changed their lives forever have been popping up all over social media. You can read more about some of these success stories on the Antinol® Facebook page (facebook.com.au/Antinol.au).

Antinol® RAPID is breaking new ground and delivering even better results for veterinarians and pet owners alike. Antinol® RAPID remains proudly a veterinary exclusive product and unlike the original it has no human equivalent.

Want to learn more about Antinol® RAPID? Email antinol@cenvet.com.au, or call 1300 CENVET.

Visit Cenvet


1. Kwananocha, I., Vijarnsorn, M., Kashemsant, N. and Lekcharoensuk, C., 2016. Effectiveness of disease modifying osteoarthritis agents and carprofen for treatment of canine osteoarthritis. Thai Journal of Veterinary Medicine, 46(3), pp.363-371.

2. Vijarnsorn, M., Kwananocha, I., Kashemsant, N., Jarudecha, T., Lekcharoensuk, C., Beale, B., Peirone, B. and Lascelles, B., 2019. The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis. BMC Veterinary Research, 15(1).


Please enter your comment!
Please enter your name here